Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAMPRASAD C DANDILLAYA

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1316900236
CMS profile
14767
Location
LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,926.54

85 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,926.54 85

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAMPRASAD C DANDILLAYA

NPI 1316900236 · CMS profile ID 14767

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1316900236?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAMPRASAD C DANDILLAYA, NPI 1316900236, CMS profile ID 14767. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316900236?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RAMPRASAD C DANDILLAYA, NPI 1316900236, CMS profile ID 14767. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316900236?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RAMPRASAD C DANDILLAYA, NPI 1316900236, CMS profile ID 14767, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1316900236?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

85 matching records · $1,926.54 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 85 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–85 of 85.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $28.7704/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086835483 CMS
Novartis Pharmaceuticals Corporation $0.7404/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086835485 CMS
Novartis Pharmaceuticals Corporation $8.6004/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086835487 CMS
Novartis Pharmaceuticals Corporation $19.6804/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086835493 CMS
Lexicon Pharmaceuticals, Inc. $17.1704/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1081728875 CMS
Novartis Pharmaceuticals Corporation $9.0404/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086835491 CMS
Amgen Inc. $24.3504/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115549414 CMS
Novartis Pharmaceuticals Corporation $18.9704/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086835489 CMS
Lilly USA, LLC $19.1304/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135328251 CMS
Alnylam Pharmaceuticals Inc. $28.0003/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125838117 CMS
Novartis Pharmaceuticals Corporation $17.2703/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086835479 CMS
Amgen Inc. $33.0903/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115549454 CMS
E.R. Squibb & Sons, L.L.C. $16.9203/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101415807 CMS
Edwards Lifesciences Corporation $27.0803/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138896689 CMS
E.R. Squibb & Sons, L.L.C. $20.6703/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101415809 CMS
Mylan Specialty L.P. $24.8902/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147322581 CMS
Novartis Pharmaceuticals Corporation $20.2402/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086835475 CMS
Novartis Pharmaceuticals Corporation $20.0502/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086835469 CMS
Amgen Inc. $16.2902/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115549445 CMS
Antares Pharma, Inc. $18.3202/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146454722 CMS
Antares Pharma, Inc. $24.2302/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146454726 CMS
ABBVIE INC. $14.1902/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103597556 CMS
ABBVIE INC. $18.9702/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103597558 CMS
Novo Nordisk Inc $21.9602/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096891031 CMS
HEARTFLOW, INC. $21.4401/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154181858 CMS
Novartis Pharmaceuticals Corporation $10.4501/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086835467 CMS
PFIZER INC. $16.9601/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130963791 CMS
Amgen Inc. $26.1101/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115549408 CMS
Exact Sciences Corporation $16.4201/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114626602 CMS
E.R. Squibb & Sons, L.L.C. $18.1801/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101415799 CMS
Alnylam Pharmaceuticals Inc. $19.6301/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125838111 CMS
Novartis Pharmaceuticals Corporation $25.1101/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086835465 CMS
Kiniksa Pharmaceuticals International, plc $20.7801/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154880572 CMS
Bayer Healthcare Pharmaceuticals Inc. $17.4101/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086144491 CMS
HEARTFLOW, INC. $22.9401/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154181856 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $735.89 37
PY2020 $950.97 42
PY2021 $1,648.45 81
PY2022 $2,035.84 78
PY2023 $1,847.32 71
PY2024 $1,926.54 85
PY2025 $2,651.19 103

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $258,757.67 72
PY2024 Principal investigator $525,347.61 130
PY2023 Recipient $1,666.02 9
PY2023 Principal investigator $155,996.16 19
PY2022 Principal investigator $115,253.13 6
PY2021 Principal investigator $665,990.07 15
PY2020 Principal investigator $45,167.70 8
PY2019 Principal investigator $6,661.69 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

72 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 12/17/2025 Non-covered Recipient Entity
Ram Dandillaya MD-Beverly Hills
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220734177
Principal investigator 1 Boehringer Ingelheim International GmbH $359.64 12/17/2025 Non-covered Recipient Entity
Ram Dandillaya MD-Beverly Hills
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220734179
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 12/17/2025 Non-covered Recipient Entity
Ram Dandillaya MD-Beverly Hills
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220734181
Principal investigator 1 GENZYME CORPORATION $280.00 12/10/2025 Non-covered Recipient Entity
Vitality Clinical Research Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226108226
Principal investigator 1 GENZYME CORPORATION $8,500.00 12/04/2025 Non-covered Recipient Entity
Vitality Clinical Research Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226108194
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 11/25/2025 Non-covered Recipient Entity
Ram Dandillaya MD-Beverly Hills
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220997416
Principal investigator 1 GlaxoSmithKline, LLC. $366.89 11/19/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192109818
Principal investigator 1 GlaxoSmithKline, LLC. $431.79 11/19/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192163248
Principal investigator 1 GlaxoSmithKline, LLC. $2,227.50 11/19/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192169266
Principal investigator 1 GlaxoSmithKline, LLC. $935.00 11/19/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192170520
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 11/19/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192170530
Principal investigator 1 GlaxoSmithKline, LLC. $15,202.75 11/12/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192165753
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 11/07/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192166947
Principal investigator 1 Janssen Research & Development, LLC $407.00 10/27/2025 Non-covered Recipient Entity
PACIFIC OAKS MEDICAL GROUP
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175442209
Principal investigator 1 Amgen Inc. $341.00 10/02/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTER INC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246646347
Principal investigator 1 Janssen Research & Development, LLC $360.00 10/02/2025 Non-covered Recipient Entity
PACIFIC OAKS MEDICAL GROUP
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175442192
Principal investigator 1 Janssen Research & Development, LLC $775.00 09/24/2025 Non-covered Recipient Entity
Pacific Oaks Medcl Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175167439
Principal investigator 1 Janssen Research & Development, LLC $5,375.00 09/19/2025 Non-covered Recipient Entity
Pacific Oaks Medcl Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175167431
Principal investigator 1 Janssen Research & Development, LLC $407.00 09/15/2025 Non-covered Recipient Entity
PACIFIC OAKS MEDICAL GROUP
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175442215
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 09/09/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192163252
Principal investigator 1 GENZYME CORPORATION $6,600.00 09/03/2025 Non-covered Recipient Entity
Vitality Clinical Research
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226149680
Principal investigator 1 Janssen Research & Development, LLC $407.00 08/29/2025 Non-covered Recipient Entity
PACIFIC OAKS MEDICAL GROUP
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175442197
Principal investigator 1 Janssen Research & Development, LLC $407.00 08/29/2025 Non-covered Recipient Entity
PACIFIC OAKS MEDICAL GROUP
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175442203
Principal investigator 1 GlaxoSmithKline, LLC. $3,561.50 08/04/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192163256
Principal investigator 1 GlaxoSmithKline, LLC. $1,322.26 08/04/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192165758
Principal investigator 1 GlaxoSmithKline, LLC. $733.05 08/01/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192163229
Principal investigator 1 GlaxoSmithKline, LLC. $67.50 08/01/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192165745
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 08/01/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192166943
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 08/01/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192166954
Principal investigator 1 GlaxoSmithKline, LLC. $540.00 08/01/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192166959
Principal investigator 1 GlaxoSmithKline, LLC. $1,350.00 08/01/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192170515
Principal investigator 1 GlaxoSmithKline, LLC. $986.85 08/01/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192170546
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 08/01/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192172234
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 07/30/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192166951
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 07/30/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192169254
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 07/30/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192169271
Principal investigator 1 Axsome Therapeutics, Inc. $15,352.64 07/29/2025 Non-covered Recipient Entity
Cure Clinical Research
An Evaluation of the Safety and Pharmacokinetics of AXS-05 Given for Eight Days in Subjects with Severe Renal Impairment Compared to Subjects with Normal Renal Function No dispute reported 06/30/2026 1199917704
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 07/28/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192165741
Principal investigator 1 Janssen Research & Development, LLC $2,508.00 07/23/2025 Non-covered Recipient Entity
Pacific Oaks Medcl Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175167459
Principal investigator 1 Novartis Pharmaceuticals Corporation $36,688.48 07/16/2025 Non-covered Recipient Entity
PACIFIC OAKS MEDICAL GROUP
Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION) No dispute reported 06/30/2026 1190302313
Principal investigator 1 Janssen Research & Development, LLC $342.00 07/11/2025 Non-covered Recipient Entity
Pacific Oaks Medcl Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175167479
Principal investigator 1 Janssen Research & Development, LLC $1,842.00 07/07/2025 Non-covered Recipient Entity
Pacific Oaks Medcl Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175167487
Principal investigator 1 Janssen Research & Development, LLC $8,990.00 06/26/2025 Non-covered Recipient Entity
Pacific Oaks Medcl Group
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175167397
Principal investigator 1 GlaxoSmithKline, LLC. $18,337.18 06/11/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192170542
Principal investigator 1 Janssen Research & Development, LLC $2,376.00 05/21/2025 Non-covered Recipient Entity
Vitality Clinic Rsrch
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175167468
Principal investigator 1 GlaxoSmithKline, LLC. $4,465.66 05/15/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192163234
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 05/12/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192170534
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 05/08/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192169262
Principal investigator 1 GlaxoSmithKline, LLC. $18,683.46 04/08/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192169258
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 04/04/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192166939
Principal investigator 1 GlaxoSmithKline, LLC. $729.00 03/21/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192163239
Principal investigator 1 GlaxoSmithKline, LLC. $67.50 03/21/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192163245
Principal investigator 1 GlaxoSmithKline, LLC. $5,230.03 03/21/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192165733
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 03/21/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192165761
Principal investigator 1 GlaxoSmithKline, LLC. $1,350.00 03/21/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192166932
Principal investigator 1 GlaxoSmithKline, LLC. $1,350.00 03/21/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192166935
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 03/21/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192172238
Principal investigator 1 GlaxoSmithKline, LLC. $540.00 03/21/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192172244
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 02/26/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192169275
Principal investigator 1 GlaxoSmithKline, LLC. $17,794.69 02/24/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192163225
Principal investigator 1 Janssen Research & Development, LLC $1,647.00 02/19/2025 Non-covered Recipient Entity
Vitality Clinic Rsrch
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175167511
Principal investigator 1 GlaxoSmithKline, LLC. $405.00 01/29/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192109812
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 01/29/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192165737
Principal investigator 1 GlaxoSmithKline, LLC. $193.05 01/29/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192169244
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 01/29/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192169249
Principal investigator 1 GlaxoSmithKline, LLC. $729.00 01/29/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192169280
Principal investigator 1 GlaxoSmithKline, LLC. $67.50 01/29/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192170525
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 01/29/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192170538
Principal investigator 1 GlaxoSmithKline, LLC. $10,381.84 01/28/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192165764
Principal investigator 1 Janssen Research & Development, LLC $11,407.00 01/22/2025 Non-covered Recipient Entity
Vitality Clinic Rsrch
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175167519
Principal investigator 1 Amgen Inc. $35,078.47 01/13/2025 Non-covered Recipient Entity
PACIFIC OAKS MEDICAL GROUP
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246646229
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 01/03/2025 Non-covered Recipient Entity
PHARMASEEK LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192165749